Scindo CEO Gustaf Hemberg will be at BioTrinity 2025, speaking about some of the pioneering work we’re doing at Scindo to accelerate the future of cell-free, enzyme-powered biomanufacturing, and how we're enabling clean feedstocks to produce the bioactive ingredients that go into everyday products—from flavours to cosmetics. He will be sharing insights on: ⚡ How cell-free systems are unlocking reaction space beyond nature 🌍 The potential for scalable, low-footprint manufacturing across industries 🤖 The role of AI in navigating massive reaction space and accelerating development.
📣 BioTrinity Programme Announcement 📣 Our science spotlight sessions at BioTrinity showcase innovative R&D companies at around Series A stage across 14 therapy areas. Below, we are pleased to highlight the companies presenting in the 'Synthetic Biology' session, which will be kindly hosted by Prof Richard Kitney: Co-Founder and Co-Director at SynbiCITE: Pedro Correa de Sampaio De Sampaio: CEO at Neobe Therapeutics Zehra Nizami: Principal Scientist at PartitionBio Ltd Gustaf Hemberg: Founder & CEO at Scindo Cai Linton: Co-founder and CEO at Multus Don’t miss this chance to attend OBN's flagship 2-day conference on 1st & 2nd April 2025. 🎟 Book your ticket today: www.biotrinity.com #LifeSciences #BiotechInnovation #OBN